Shares of Glaukos Corporation (GKOS) reached a 52-week high of $151.12, reflecting investor optimism surrounding the company's continued progress and innovation in ophthalmic treatments.
Glaukos is an ophthalmic medical technology and pharmaceutical company focused on developing innovative therapies for glaucoma, corneal health, and retinal diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com